IntelGenx Technologies Corp (IGXT)

[bUrRpPPP!]

CBD market

There are not many sectors more crowded these days than cannabis. IntelGenx has two deals ongoing for these type of products. One is with Tilray for a medical cannabinoid that has completed manufacturing scale-up and will launch in 2020. The other is with Tetra BioPharma for a pain-focused dronabinol drug that is already available outside the US and Canada.

In this market, regulatory issues can be a major barrier with this controversial compound. Zerbe explains: “It has been very difficult to keep up with the rapidly evolving and changing legal landscape surrounding edible cannabis products. In order to be able to keep up, we have involved an Ottawa-based consulting firm that specialises in cannabis legislation and the various application procedures.”

In spite of these regulatory complications, oral films are a smart way to differentiate and improve a product in an oversaturated market.
Sign up for your free email newsletter

Whether for crowded markets or drugs with low bioavailability, oral films are an exciting innovation showing potential to provide a win-win for patients and businesses alike.